US approves first blood test for Alzheimer's, enabling earlier diagnosis and treatment
WASHINGTON, May 17 — The United States yesterday approved the first blood test for Alzheimer's, a move that could help patients begin treatment earlier with newly approved drugs that slow the progression of the devastating neurological disease.
The test, developed by Fujirebio Diagnostics, measures the ratio of two proteins in the blood. The rato is correlated with amyloid plaques in the brain—a hallmark of Alzheimer's that, until now, has been detected only through brain scans or spinal fluid analysis.
'Alzheimer's disease impacts too many people—more than breast cancer and prostate cancer combined,' said Food and Drug Administration Commissioner Marty Makary.
'Knowing that 10 percent of people aged 65 and older have Alzheimer's, and that by 2050 that number is expected to double, I am hopeful that new medical products such as this one will help patients.'
There are currently two FDA approved treatments for Alzheimer's: lecanemab and donanemab, which target amyloid plaque and have been shown to modestly slow cognitive decline, though they do not cure the disease.
Advocates for the intravenous antibody therapies, including many neurologists, say they can offer patients a few additional months of independence—and are likely to be more effective if started earlier in the disease's course.
In clinical studies, the blood test produced results largely in line with positron emission tomography (PET) brain scans and spinal fluid analysis.
'Today's clearance is an important step for Alzheimer's diagnosis, making it easier and potentially more accessible for US patients earlier in the disease,' said Michelle Tarver of the FDA's Center for Devices and Radiological Health.
The test is authorized for use in clinical settings for patients showing signs of cognitive decline, and results must be interpreted alongside other clinical information.
Alzheimer's is the most common form of dementia. It worsens over time, gradually robbing people of their memories and independence. — AFP
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
19 hours ago
- Malaysian Reserve
Elon Musk's Neuralink closes Series E funding round
SAN FRANCISCO — Elon Musk's (picture) brain computer interface startup Neuralink announced on Monday that it has closed a US$650 million funding round, Xinhua reported. The Series E fundraiser included investors such as ARK Invest, Founders Fund, Sequoia Capital, and Thrive Capital, among others, the company said in a blog post. Neuralink last raised a US$280 million Series D funding round in 2023, with an additional US$43 million tranche added months later. The company said it has now conducted more human clinical trials, implanting its brain chips in five individuals with severe paralysis. In May, Neuralink received a Breakthrough Devices Programme designation from the US Food and Drug Administration (FDA). The Breakthrough Devices Programme is a voluntary programme for certain medical devices and device-led combination products that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions, according to the FDA. The programme is intended to provide patients and healthcare providers with timely access to medical devices by speeding up development, assessment, and review for premarket approval. — BERNAMA-XINHUA
Free Malaysia Today
21 hours ago
- Free Malaysia Today
New hope for patients with less common breast cancer
Results from a new study could soon establish a new first-line therapy for people with HER2-positive metastatic breast cancer. (Envato Elements pic) WASHINGTON : A new treatment nearly halves the risk of disease progression or death from a less common form of breast cancer that hasn't seen major drug advances in over a decade, researchers reported Monday. Results from the study, presented at the annual meeting of the American Society for Clinical Oncology, are expected to be submitted to regulators and could soon establish a new first-line therapy for people with HER2-positive metastatic breast cancer – the advanced stage of a form that comprises 15–20% of all breast cancer cases. HER2-positive cancers are fuelled by an overactive HER2 gene, which makes too much of a protein called human epidermal growth factor receptor 2 that helps cancer cells grow and spread. Patients with HER2-positive breast cancer that has spread to other parts of the body live around five years. 'Seeing such a striking improvement was really impressive to us – we were taking a standard and almost doubling how long patients could have their cancer controlled for,' oncologist Sara Tolaney, chief of the breast oncology division at Dana-Farber Cancer Institute, told AFP. The current standard of care, known as THP, combines chemotherapy with two antibodies that block growth signals from the HER2 protein. The new approach uses a drug called trastuzumab deruxtecan (T-DXd), an antibody attached to a chemotherapy drug. 'Smart bomb' This 'smart bomb' strategy allows the drug to target cancer cells directly. 'You can bind to the cancer cell and dump all that chemo right into the cancer cells,' explained Tolaney. 'Some people call them smart bombs because they're delivering chemo in a targeted fashion – which is how I think we're able to really increase efficacy so much.' Common side effects included nausea, diarrhea and a low white blood cell count, with a less common effect involving lung scarring. T-DXd is already approved as a 'second-line' option – used when first-line treatments stop working. But in the new trial, it was given earlier, paired with another antibody, pertuzumab. In a global trial led by Tolaney, just under 400 patients were randomly assigned to receive T-DXd in combination with pertuzumab, thought to enhance its effects. A similar number received the standard THP regimen. A third group, who received T-DXd without pertuzumab, was also enrolled — but those results haven't yet been reported. 44% risk reduction At a follow-up of 2.5 years, the T-DXd and pertuzumab combination reduced the risk of disease progression or death by 44% compared to standard care. Meanwhile, 15% of patients in the T-DXd group saw their cancer disappear entirely, compared to 8.5% in the THP group. Because this was an interim analysis, the median progression-free survival – meaning the point at which half the patients had seen their cancer return or worsen – was 40.7 months with the new treatment, compared to 26.9 months with the standard, and could rise further as more data come in. Tolaney said the results would be submitted to regulators around the world, including the US Food and Drug Administration, and that future work would focus on optimizing how long patients remain on the treatment, particularly those showing complete remission. 'This represents a new first-line standard treatment option for HER2-positive metastatic breast cancer,' said Dr. Rebecca Dent, a breast cancer specialist at the National Cancer Center Singapore who was not involved in the study
Free Malaysia Today
21 hours ago
- Free Malaysia Today
Living near green spaces could reduce risk of premature birth
Mothers living in areas where new trees are planted are more likely to give birth at term, with babies of higher weights, researchers say. (Envato Elements pic) PARIS : The benefits of green spaces for human health are well established – they have been shown, for example, to promote physical activity, and reduce stress and pollution. But proximity to nature also has an impact on the number of premature births, according to a recent US study published in the journal Science of the Total Environment. Conducted by professors at Drexel University in Philadelphia, this research followed over 36,000 pregnant women who gave birth between Jan 1, 2015, and Dec 31, 2020, residing in Portland, Oregon, where over 36,000 trees were planted between 1990 and 2020. The number of trees planted within a 100m radius of the participants' addresses was evaluated. 'We found that tree planting around maternal address was associated with increased birthweight as well as a reduced probability of a small-for-gestational-age or preterm birth,' the researchers wrote. In other words, mothers living in areas where trees were planted within the past 30 years were more likely to give birth at term, with babies of higher birth weights, than those living farther away from tree-planted areas. Specifically, living within 100m of at least 10 trees is associated with an increase of about 50g in birth weight, which was the case for 2,879 babies in the sample studied. 'This might not seem like a lot, but if every baby in our sample gained 50g at birth, that means 642 fewer babies considered small for gestational age and at higher risk for worse development later in life,' said senior author Yvonne Michael. The study also notes that older trees may provide some additional benefits compared to those recently planted, such as improved air quality and reduced noise pollution from road traffic. This study isn't the first to highlight a link between a reduction in premature births and proximity to green space. But the novelty lies in its methodology, which focuses on recently planted trees and over a precise period. 'Existing tree cover is often closely tied to factors like income, education and race, making it difficult to fully account for other possible explanations when studying birth outcomes. By focusing on newly planted trees, we were able to reduce the bias – essentially treating it as a natural experiment,' Michael explained. 'This is another data point showing that planting trees is a relatively easy and low-cost way to improve public health from the earliest stages of life,' she concluded.
